Keyphrases
Placebo
100%
Peru
100%
Randomized Clinical Trial
100%
COVID-19
100%
Randomized Controlled Trial
100%
Nasopharyngeal
100%
Ivermectin
100%
Structured Summaries
100%
Saints
100%
Nasopharyngeal Swab
30%
Consecutive Days
23%
Pharmacist
23%
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
15%
Principal Investigator
15%
Clinical Trials
15%
Fever
15%
Statistician
15%
Patient's Will
15%
Epidemiologist
15%
Cough
15%
Daily Dose
15%
PCR Test
15%
Rapid Diagnostic Test
15%
Moderate COVID-19
15%
SARS-CoV-2 PCR
15%
Virus
7%
Immune Response
7%
Symptomatology
7%
Risk Factors
7%
Lung
7%
Oxygen Saturation
7%
Clinical Care
7%
Hospitalization
7%
Randomized Placebo-controlled Trial
7%
Pregnant Women
7%
Severe Disease
7%
Luminex
7%
Day 14
7%
Treatment Group
7%
Clinical Parameters
7%
National Health
7%
Viral Load
7%
Tacrolimus
7%
SARS-CoV-2 Infection
7%
One Dose
7%
Treatment Initiation
7%
Nasopharyngeal Specimens
7%
Ritonavir
7%
Medical Staff
7%
Seroconversion
7%
Cyclosporine
7%
Trial Registration
7%
Erythromycin
7%
Indinavir
7%
National Hospital
7%
Active Substances
7%
Itraconazole
7%
Amiodarone
7%
Inhibitor Drug
7%
Placebo Groups
7%
Peruvian
7%
Verapamil
7%
Clarithromycin
7%
Spironolactone
7%
Diltiazem
7%
Ketoconazole
7%
Lima
7%
Laboratory Parameters
7%
Attending Physicians
7%
Health Institutes
7%
Cytochrome P450 3A4 (CYP3A4)
7%
Treatment Assignment
7%
Childbearing
7%
Quinidine
7%
19th Century
7%
Warfarin
7%
Drug Adverse Events
7%
CYP3A4 Substrates
7%
Median Level
7%
Pregnancy Test
7%
Randomized Blocks
7%
Intestinal Helminths
7%
Anosmia
7%
Trial Design
7%
Emergency Service
7%
Clinical Participants
7%
Severe COVID-19 Disease
7%
Cobicistat
7%
SARS-CoV-2 Detection
7%
COVID-19 Treatment
7%
Cycle Threshold
7%
SARS-CoV-2 RNA
7%
Severe COVID-19 Patients
7%
COVID-19 Pneumonia
7%
COVID-19 Progression
7%
SARS-CoV-2 Viral Load
7%
Substrate Drugs
7%
Afectividad
7%
Version 2.0
7%
Arms Allocation
7%
P-gp Inhibitor
7%
PCR Cycles
7%
Pacientes
7%
Encrypted Files
7%
Medicine and Dentistry
Placebo
100%
Randomized Clinical Trial
100%
COVID-19
100%
Randomized Controlled Trial
100%
Ivermectin
100%
Severe Acute Respiratory Syndrome Coronavirus 2
50%
Nasopharyngeal Swab
28%
Clinical Trial
14%
Disease
14%
Epidemiologist
14%
SARS Coronavirus
14%
Coughing
14%
Arm
14%
Rapid Diagnostic Test
14%
Adverse Event
7%
Infection
7%
Immune Response
7%
Oxygen Saturation
7%
Population Research
7%
Immunoglobulin M
7%
Immunoglobulin A
7%
Seroconversion
7%
Symptomatology
7%
Tacrolimus
7%
Cyclosporine
7%
Triage
7%
Amiodarone
7%
Verapamil
7%
Erythromycin
7%
Spironolactone
7%
Warfarin
7%
Ketoconazole
7%
Itraconazole
7%
Masking
7%
Diltiazem
7%
Pregnancy Test
7%
Helminth
7%
Lung Examination
7%
Clarithromycin
7%
Quinidine
7%
Anosmia
7%
CYP3A4
7%
Cobicistat
7%
Indinavir Plus Ritonavir
7%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Randomized Clinical Trial
100%
Randomized Controlled Trial
100%
Ivermectin
100%
SARS Coronavirus
64%
Clinical Trial
14%
Disease
14%
Coughing
14%
Adverse Event
7%
Infection
7%
Symptomatology
7%
Tacrolimus
7%
Immunoglobulin A
7%
Population Study
7%
Ciclosporin
7%
Immunoglobulin M
7%
Amiodarone
7%
Verapamil
7%
Clarithromycin
7%
Erythromycin
7%
Spironolactone
7%
Diltiazem
7%
Ketoconazole
7%
CYP3A4
7%
Warfarin
7%
Itraconazole
7%
Quinidine
7%
Helminth
7%
Cobicistat
7%
Anosmia
7%
Indinavir Plus Ritonavir
7%
Nursing and Health Professions
Placebo
100%
Ivermectin
100%
Severe Acute Respiratory Syndrome
64%
Randomization
28%
Disease
14%
Virus Load
14%
Sample Size
14%
Epidemiologist
14%
Diagnostic Test
14%
Coughing
14%
Oxygen Saturation
7%
Medical Staff
7%
Health Center
7%
Infection
7%
Adverse Event
7%
Symptomatology
7%
Immunoglobulin M
7%
Triage
7%
Ciclosporin
7%
Ketoconazole
7%
Clarithromycin
7%
Warfarin
7%
Erythromycin
7%
Immunoglobulin A
7%
Tacrolimus
7%
Pregnancy Test
7%
Verapamil
7%
Amiodarone
7%
Masking
7%
Itraconazole
7%
Diltiazem
7%
Anosmia
7%
Lung Examination
7%
CYP3A4
7%
Cobicistat
7%
Spironolactone
7%
Indinavir Plus Ritonavir
7%
Quinidine
7%